Better health for women involved in clinical trials
Women who participate in obstetric and gynaecology clinical trials experience improved health outcomes compared to those who are not involved in trials, according to research by Queen Mary University of London (QMUL). This is the case regardless of whether or not the treatment is found to be effective in the trial.
The review of 21 studies* included 20,160 women, and found that participants had 25 per cent better odds of improved health outcomes**, compared with non-participants. The researchers hope the results may lead to more clinicians offering trials to their patients and more women volunteering for trials in a research area that currently faces many challenges.
A clinical trial compares the effects of one treatment with another, and normally involves large numbers of volunteer patients in many centres. The results from trials help doctors understand how to treat a particular disease or condition, and are necessary to test the safety and efficacy of new treatments before they are brought into general use.
Research on the effect of participation in trials has previously not consistently shown evidence of benefit. This may be because previous work has analysed data from all medical specialities grouped together which could include wide variations in the way care is given within and outside trials.
The review, which focuses on pregnancy and reproductive health, is published in BJOG: An International Journal of Obstetrics and Gynaecology (BJOG) and is believed to be the first of its kind. It found that the beneficial effect of participating in a trial was largest when it was a high quality clinical trial, and when the trial tested an intervention that was unavailable outside of the trial.
Lead researcher Professor Khalid Khan from QMUL said: "Clinical trials are often perceived as 'experiments', 'risky' or 'dangerous'. However, our findings challenge these misconceptions, and show not only that they are safe but that there is a significant benefit associated with participation, with overall 25 per cent chance of better health outcomes."
"Interestingly, we also found that participants still experienced benefits irrespective of whether the treatment in the trial was found to be effective or not."
Worldwide over 69 million babies are born annually (776,000 in the UK), but only a small proportion of pregnant women are entered into research studies. Pregnancy and reproductive health is an area with unique challenges, dealing with controversial topics (IVF, contraception, abortion), a lack of research funding (less than one per cent of UK government spend) and ethical/legal implications (studies involving pregnant women). As such, research results from general medicine often inform practise in pregnancy patients, which does not always lead to optimum medical care.
Ngawai Moss was a participant of QMUL's EMPiRE trial – a study looking at how to control seizures in pregnant women with epilepsy. She said: "I'm very happy that I took part in a clinical trial and would do it all over again without hesitation. I would tell women who are considering whether to join a clinical trial, that the investment of their time is really quite minimal for the reward.
"In my case, the trial was pretty straightforward and mainly involved monthly visits to fill in a questionnaire and have a blood test. It was reassuring to be able to see a medical professional on a regular basis, especially as I had a complicated pregnancy. It meant I had access to the team's medical insight, advice and support on general pregnancy-related issues."
Professor Khalid Khan from QMUL added: "Women in general are often unrepresented in research, so we hope this may lead to a shift in attitudes and encourage more clinicians and women to be involved in trials. We also hope that patients recognise that research can be even safer than routine healthcare, due to the additional safeguards in place."
The researchers say that it is important to remember that research can still be associated with risk, and it is the duty of researchers and clinicians to inform patients of the potential risk and benefit of engagement in research.
QMUL's IBIS 3 Feasibility Study is currently looking to recruit post-menopausal breast cancer survivors. The clinical trial will test three types of medicines in 18 hospitals around the UK to find out the best way to prevent the late recurrence of breast cancer. More information on joining the trial is available on the website or by contacting [email protected] or 020 7882 3510.
For more information, please contact:
Queen Mary University of London Press Office
Tel: +44 (0) 20 7882 3004
Notes to the editor
* Example trials analysed in the review included a trial on the use of heparin and aspirin for women with in vitro fertilization implantation failure, and a trial comparing the success of hormone releasing implants with copper-intrauterine devices as contraceptive methods.
** The review included maternal and neonatal health outcomes such as stillbirth, pre-eclampsia, pregnancy rates, Neural tube defect, spontaneous fetal death, treatment satisfaction, treatment acceptability, infant death, caesarean section rate, successful surgery, severe bleeding (abortion), and fetal outcomes.
Research paper: 'Participation in clinical trials improves outcomes in women's health: A systematic review and meta-analysis'. Simrit K. Nijjar, Maria I. D'Amico, Noshali A. Wimalaweera, Natalie A.M. Cooper, Javier Zamora, Khalid S. Khan. BJOG 2017. DOI: 10.1111/1471-0528.14528. Once published, the article can be found here: http://onlinelibrary.wiley.com/doi/10.1111/1471-0528.14528/full
About Queen Mary University of London
Queen Mary University of London (QMUL) is one of the UK's leading universities, and one of the largest institutions in the University of London, with 21,187 students from more than 155 countries.
A member of the Russell Group, we work across the humanities and social sciences, medicine and dentistry, and science and engineering, with inspirational teaching directly informed by our research. In the most recent national assessment of the quality of research, we were placed ninth in the UK (REF 2014).
As well as our main site at Mile End – which is home to one of the largest self-contained residential campuses in London – we have campuses at Whitechapel, Charterhouse Square, and West Smithfield dedicated to the study of medicine, and a base for legal studies at Lincoln's Inn Fields.
We have a rich history in London with roots in Europe's first public hospital, St Barts; England's first medical school, The London; one of the first colleges to provide higher education to women, Westfield College; and the Victorian philanthropic project, the People's Palace at Mile End.
Today, as well as retaining these close connections to our local community, we are known for our international collaborations in both teaching and research.
QMUL has an annual turnover of £350m, a research income worth £125m (2014/15), and generates employment and output worth £700m to the UK economy each year.